Overview

• MK-8527 is a nucleoside reverse transcriptase translocation inhibitor developed through lead optimization starting from islatravir.
• In vitro testing showed robust antiviral activity, and animal pharmacokinetics indicated suitability for long-acting oral therapy compatible with monthly dosing.
• Human studies are under way to evaluate safety and tolerability in volunteers at low likelihood of HIV exposure, with at least one completed early study reported as promising.
• Researchers note that a monthly oral option could improve adherence, privacy and access compared with daily pills or provider-administered injections.
• The findings were published August 26, 2025 in PLOS Biology, and larger efficacy trials plus subsequent regulatory review will determine potential use in prevention programs.